JP2008535475A5 - - Google Patents

Download PDF

Info

Publication number
JP2008535475A5
JP2008535475A5 JP2007556317A JP2007556317A JP2008535475A5 JP 2008535475 A5 JP2008535475 A5 JP 2008535475A5 JP 2007556317 A JP2007556317 A JP 2007556317A JP 2007556317 A JP2007556317 A JP 2007556317A JP 2008535475 A5 JP2008535475 A5 JP 2008535475A5
Authority
JP
Japan
Prior art keywords
antibody
polypeptide
composition
therapeutic agent
nucleic acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2007556317A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008535475A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2006/005615 external-priority patent/WO2006112930A2/en
Publication of JP2008535475A publication Critical patent/JP2008535475A/ja
Publication of JP2008535475A5 publication Critical patent/JP2008535475A5/ja
Pending legal-status Critical Current

Links

JP2007556317A 2005-02-18 2006-02-17 Ｑ３ｓｐａｒｃ欠失変異体及びその使用 Pending JP2008535475A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US65426105P 2005-02-18 2005-02-18
PCT/US2006/005615 WO2006112930A2 (en) 2005-02-18 2006-02-17 Q3 sparc deletion mutant and uses thereof

Publications (2)

Publication Number Publication Date
JP2008535475A JP2008535475A (ja) 2008-09-04
JP2008535475A5 true JP2008535475A5 (https=) 2009-04-02

Family

ID=37000156

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2007556317A Pending JP2008535475A (ja) 2005-02-18 2006-02-17 Ｑ３ｓｐａｒｃ欠失変異体及びその使用

Country Status (7)

Country Link
US (3) US7332568B2 (https=)
EP (1) EP1869077A2 (https=)
JP (1) JP2008535475A (https=)
CN (1) CN101160321A (https=)
AU (1) AU2006237613A1 (https=)
CA (1) CA2598510C (https=)
WO (1) WO2006112930A2 (https=)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070117862A1 (en) * 1993-02-22 2007-05-24 Desai Neil P Novel formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof
US5439686A (en) * 1993-02-22 1995-08-08 Vivorx Pharmaceuticals, Inc. Methods for in vivo delivery of substantially water insoluble pharmacologically active agents and compositions useful therefor
US8137684B2 (en) 1996-10-01 2012-03-20 Abraxis Bioscience, Llc Formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof
US8853260B2 (en) * 1997-06-27 2014-10-07 Abraxis Bioscience, Llc Formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof
CA2509365C (en) * 2002-12-09 2012-08-07 American Bioscience, Inc. Compositions and methods of delivery of pharmacological agents
US8735394B2 (en) 2005-02-18 2014-05-27 Abraxis Bioscience, Llc Combinations and modes of administration of therapeutic agents and combination therapy
KR20070114753A (ko) * 2005-02-18 2007-12-04 아브락시스 바이오사이언스 인크. 치료제의 조합 및 투여 방식, 및 조합 요법
EP3527202A1 (en) * 2005-08-31 2019-08-21 Abraxis BioScience, LLC Compositions and methods for preparation of poorly water soluble drugs with increased stability
LT3311805T (lt) 2005-08-31 2020-04-27 Abraxis Bioscience, Llc Kompozicijos, apimančios silpnai vandenyje tirpius farmacinius agentus ir priešmikrobinius agentus
US8440625B2 (en) 2006-06-26 2013-05-14 University Of British Columbia Secreted protein acidic and rich in cysteine (SPARC) as chemotherapeutic sensitizers
US20080280987A1 (en) * 2006-08-31 2008-11-13 Desai Neil P Methods of inhibiting angiogenesis and treating angiogenesis-associated diseases
WO2015081096A2 (en) * 2013-11-26 2015-06-04 The Brigham And Women's Hospital, Inc. Receptor-targeted nanoparticles for enhanced transcytosis mediated drug delivery
ES2389828T3 (es) * 2007-04-13 2012-11-02 Abraxis Bioscience, Inc. Composiciones que comprenden polipéptidos SPARC
EP2257626A2 (en) * 2008-03-01 2010-12-08 Abraxis BioScience, LLC Treatment, diagnostic, and method for discovering antagonist using sparc specific mirnas
MX2010011165A (es) * 2008-04-10 2011-02-22 Abraxis Bioscience Llc Composiciones de derivados de taxano hidrofobos y sus usos.
JP2011516609A (ja) * 2008-04-14 2011-05-26 アブラクシス バイオサイエンス リミテッド ライアビリティー カンパニー Ｓｐａｒｃ抗炎症活性及びその使用
AU2013228006B2 (en) * 2008-12-05 2016-05-12 Abraxis Bioscience, Llc Albumin binding peptide-mediated disease targeting
BRPI0922789A2 (pt) * 2008-12-05 2019-10-15 Abraxis Bioscience Llc peptídeo de ligação de albumina intermediador para reconhecimento de doença
BRPI0923155A2 (pt) * 2008-12-05 2018-10-23 Abraxis Bioscience Llc scfcs de ligação a sparc
WO2010105097A2 (en) * 2009-03-11 2010-09-16 Abraxis Bioscience, Llc Sparc angiogenic domain and methods of use
AU2010295324B2 (en) * 2009-09-18 2015-04-30 Abraxis Bioscience, Llc Use of the SPARC microenvironment signature in the treatment of cancer
EP3141245A1 (en) 2010-03-29 2017-03-15 Abraxis BioScience, LLC Methods of treating cancer
MX2012011155A (es) 2010-03-29 2012-12-05 Abraxis Bioscience Llc Metodos para mejorar suministros de farmacos y efectividad de agentes terapeuticos.
MX2012013874A (es) 2010-06-03 2013-01-24 Abraxis Bioscience Llc Uso de la signatura en el microentorno de sparc en el tratamiento de cancer.
CA2801184A1 (en) * 2010-06-03 2011-12-08 Abraxis Bioscience, Llc Peripheral blood sparc binding antibodies and uses thereof
MX347225B (es) 2010-06-04 2017-04-19 Abraxis Bioscience Llc * Metodos de tratamiento contra el cancer pancreatico.

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6270961B1 (en) * 1987-04-01 2001-08-07 Hyseq, Inc. Methods and apparatus for DNA sequencing and DNA identification
US5128247A (en) * 1989-08-14 1992-07-07 Board Of Regents, The University Of Texas System Methods for isolation of nucleic acids from eukaryotic and prokaryotic sources
US5130423A (en) * 1990-07-13 1992-07-14 Microprobe Corporation Non-corrosive compositions and methods useful for the extraction of nucleic acids
CA2155186A1 (en) * 1993-02-01 1994-08-18 Kevin M. Ulmer Methods and apparatus for dna sequencing
KR960701988A (ko) * 1993-04-20 1996-03-28 윌리엄 에스. 로빈슨 세포내 감염원에 감염된 개체의 치료방법 및 치료물질(methods and materials for treatment of individuals infected with intracellular in-fectious agents)
US5945515A (en) * 1995-07-31 1999-08-31 Chomczynski; Piotr Product and process for isolating DNA, RNA and proteins
CA2278678A1 (en) * 1997-01-31 1998-08-06 Research Corporation Technologies, Inc. Cancer immunotherapy with semi-allogeneic cells
DE19740571C1 (de) * 1997-09-15 1999-03-18 Gsf Forschungszentrum Umwelt Verfahren zur Stimulation von T-Zellen mit gewünschter Antigenspezifität
US6316193B1 (en) * 1998-10-06 2001-11-13 Origene Technologies, Inc. Rapid-screen cDNA library panels
US20040018188A9 (en) 1999-01-20 2004-01-29 Incyte Genomics, Inc. Sparc-related proteins
US20020015950A1 (en) * 1999-07-07 2002-02-07 Karen Anne Jones Atherosclerosis-associated genes
US6387664B1 (en) * 1999-02-26 2002-05-14 Secretary Of Agency Of Industrial Science And Technology Sparc fusion protein and method for producing the same
ATE451835T1 (de) 1999-09-24 2010-01-15 Mayo Foundation Therapeutische verfahren und zusammensetzungen unter verwendung von viren der rekombinanten familie der paramyxoviridae
WO2001081631A1 (en) 2000-04-25 2001-11-01 Dna Sciences, Inc. Detection of nucleotide sequence variations via the proofreading activity of polymerases
WO2002090544A2 (en) 2001-05-04 2002-11-14 Hybrigenics Protein-protein interactions in adipocyte cells (3)
AU2003281325A1 (en) 2002-07-02 2004-01-23 The Johns Hopkins University Secreted and cytoplasmic tumor endothelial markers
US6919504B2 (en) * 2002-12-19 2005-07-19 3M Innovative Properties Company Flexible heat sink
WO2004064785A2 (en) * 2003-01-14 2004-08-05 Dana Farber Cancer Institute Cancer therapy sensitizer
JP2007525167A (ja) * 2003-04-01 2007-09-06 ジェンザイム・コーポレーション 乳房内皮細胞発現パターン
EP2784082B1 (en) 2004-05-14 2017-12-27 Abraxis BioScience, LLC Disease site-delivering pharmaceutical compositions comprising paclitaxel.

Similar Documents

Publication Publication Date Title
JP2008535475A5 (https=)
US11466085B2 (en) Anti-PD-L1 nanobody, coding sequence and use thereof
CN111683968B (zh) 结合至cd137和psma的分子
CN109963591B (zh) B7h3抗体-药物偶联物及其医药用途
JP7690285B2 (ja) 結合タンパク質１
CN112480253B (zh) 一种抗pd-l1纳米抗体及其衍生物和用途
CN107686520B (zh) 抗pd-l1纳米抗体及其应用
JP7097636B2 (ja) 抗Ｈｅｒ２ナノボディ及びそのコード序列と用途
ES2647823T3 (es) Anticuerpos anti-CD100 y métodos de uso de los mismos
JP3171268B2 (ja) 治療抗体基融合タンパク質
CN114195900B (zh) 一种抗4-1bb/pd-l1双特异性抗体及其用途
CN108473590B (zh) 治疗分子
CN110835371A (zh) 抗ccr8单克隆抗体及其应用
JP2003284577A (ja) 癌マーカー用生物合成結合蛋白質
CN112794911B (zh) 人源化抗叶酸受体1抗体及其应用
WO2016112855A1 (zh) 抗cd19单克隆抗体及其制备方法
CA2598510A1 (en) Q3 sparc deletion mutant and uses thereof
CN113461825B (zh) 一种抗pd-l2纳米抗体及其应用
CN117304315B (zh) 抗il-6的纳米抗体及其在il-6相关疾病中的应用
JP2020535110A (ja) 分子誘導システムペプチド及びその使用
TWI906795B (zh) 特異性結合Ｃｌａｕｄｉｎ １８.２的抗體及其製法和應用
JP2024508886A (ja) 抗体－オリゴヌクレオチドコンジュゲートを使用した標的化の増強
CN114685666B (zh) 抗间皮素纳米抗体及其应用
CN120383679A (zh) 抗FAP单域抗体、Fc融合蛋白、免疫缀合物及其应用
CN115124621B (zh) 靶向pd-l1的纳米抗体及其制备方法和应用